Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 6/20 | 0.75 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.75 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.75 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.75 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.75 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.75 |
| ▸ | MDH2 | P40926 | 12/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237362 | 0.90 | CDK1 (0.81) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL5235565 | 0.88 | CDK1 (0.79) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL5233378 | 0.86 | CDK1 (0.76) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL5237969 | 0.82 | CDK1 (0.70) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL5688237 | 0.79 | GSK3B (1.00) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL14139515 | 0.71 | CDK1 (0.53) | CDK1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL7498410 | 0.69 | CDK1 (0.56) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL14608901 | 0.69 | CDK1 (0.52) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL678157 | 0.69 | CDK1 (0.54) | CDK1GSK3BCCNB2CCNB1CCNB3 | |
| SCHEMBL7493045 | 0.68 | CDK1 (0.57) | CDK1GSK3BCCNB2CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| EP-1086105-B1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US GOV HEALTH & HUMAN SERV (US) | 2006-03-01 | — | — | EP | claimed |
| US-6610684-B2 | Antiproliferative agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-08-26 | — | — | US | claimed |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE, THE | 2002-04-11 | — | — | US | claimed |
| EP-1086105-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065910-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-23 | — | — | WO | claimed |
| CN-115969814-A | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | 法斯瑞斯公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1086105-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065910-A9 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US HEALTH (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999065910-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | CDK1 1069/4885GSK3B 387/4885CCNB2 1223/4885 |
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | CDK1 435/4885GSK3B 3/4885CCNB2 2747/4885 |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | CDK1 1069/4885GSK3B 387/4885CCNB2 1223/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CDK1 142/4885GSK3B 37/4885CCNB2 798/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | CDK1 999/4885GSK3B 222/4885CCNB2 718/4885 |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | CCNI, CCNK, CDKN1A | CDK1 13/4885GSK3B 4154/4885CCNB2 61/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CDK1 142/4885GSK3B 37/4885CCNB2 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.